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Abstract
Background: Although this effect is well known, tailored treatment methods have not yet been broadly adopted.
The aim of this study was to identify those patient characteristics that most influence the impairment of quality of
life and thus to identify those patients who need and can benefit most from specific intervention treatment.
Methods: 1879 cancer patients were given the EORTC QLQ C-30 questionnaire at the beginning and end of their
inpatient rehabilitation. Patients’ scores were compared to those of 2081 healthy adults (Schwarz and Hinz, Eur J
Cancer 37:1345–1351, 2001). Furthermore, differences in quality of life corresponding to sex, age, tumor site, TNM
stage, interval between diagnosis and rehabilitation, and therapy method were examined.
Results: Compared to the healthy population, the study group showed a decreased quality of life in all analyzed
domains. This difference diminished with increasing age. Women reported a lower quality of life then men in
general. Patients with prostate cancer showed the least impairment in several domains. Patients having undergone
chemotherapy as well as radiotherapy were impaired the most. Surprisingly, TNM stage and interval between
diagnosis and rehabilitation did not significantly influence quality of life. Global quality of life and all functional
domains significantly improved after a 3-week rehabilitation program.
Conclusions: Despite an individualized and increasingly better tolerable therapy, the quality of life of cancer
patients is still considerably impaired. However, systematic screening of psychosocial aspects of cancer, e.g. quality
of life, could enable improved intervention.
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Background
The term “Health Related Quality Of Life” (HRQOL)
describes the influence of a person's health status as
reflected in his quality of life. Oncological patients
often report a strong impairment of HRQOL com-
pared to the healthy population [1, 2]. Numerous
possible causes have been discussed including the
following:
1. Although survival rates are on the rise and cancer is
increasingly developing from a lethal to a chronic
disease [3], it is still the most dreaded disease in
Germany [4].
2. Information about current and increasingly better
tolerable treatment modalities is not very
widespread.
3. The mental coping with a cancer diagnosis
accompanied by fear, helplessness and despair is a
major challenge for most patients.
4. Cancer related fatigue (CRF) is the most commonly
reported symptom [5–9]. CRF is experienced as a
physical, cognitive or emotional exhaustion, much
greater than the normal level of every-day exhaus-
tion and which is not improved by recreation pe-
riods alone [8, 9]. Multiple domains of HRQOL are
affected by CRF, especially patients’ physical and
emotional functioning [5, 7, 8].
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5. Many patients report a distinct change in their
social environment during their illness. Not only do
others withdraw from patients, out of insecurity as
to how to interact with the patient or the fear of not
being able to cope, but patients themselves withdraw
from others because they also feel insecure or do
not want to burden others with their troubles. As a
result, valuable social impulses for the patients
become rare.
6. Last but not least, in many cases the enduring
period of disease will pose a financial challenge to
the patients when costs rise due to additional
contributions to medical treatment, external
household help, etc. while incomes decline due to
sickness leave and retirement payments being lower
than previous earnings.
Since 1980, many scientific papers concerning the
various domains of HRQOL in tumor patients have
been published worldwide [10]. For several HRQOL
domains and symptom items correlations with patients’
survival rates have been found [5, 11–14]. As a conse-
quence, the investigation of HRQOL has received the
same level of importance as biometric data and clinical
parameters in many studies. However, HRQOL remains
impaired in affected patients. The aim of the current
study was to detect certain features of patients that
influence the severity of impairment of HRQOL in a
large cohort of German cancer patients. Interesting
factors were age, sex, tumor site, TNM stage, treatment
method, and time interval between diagnosis and study
participation. Thus, hopefully the results can support
the development and broad implementation of inter-
vention programs especially for those patients who
need it the most.
Methods
Procedure
Between September, 2007 and May, 2011 all oncological
patients admitted to the rehabilitation clinic were given
the EORTC-QLQ C-30 [15] to complete at the begin-
ning and end of their inpatient rehabilitation. During
their initial examination with the doctor in charge, they
were informed about the use of their questionnaires.
The only exclusion criterion was insufficient skills of the
German language.
Sample
N = 1879 patients were recruited for the study. They had
a mean age of 57.03 years (SD = 11.41) and were mostly
female (71 %). The time interval between first diagnosis
and rehabilitation averaged 16.3 months. The most com-
mon diagnosis was breast cancer (45 %), followed by
leukemia/lymphomas (13 %), colorectal cancer (12 %)
and malignancies of the female genital organs (9 %).
31 % of the patients had received both chemotherapy
and radiotherapy. 23 % had only received chemotherapy
and 24 % had only received radiotherapy. The T and N
stage distribution are depicted in Fig. 1. Only 9 % of all
patients had metastatic disease.
Measures
The EORTC QLQ C30 is presently the most frequently
used questionnaire on this topic in Europe [9]. It divides
health related quality of life into five functional domains
(physical functioning, role functioning, emotional func-
tioning, cognitive functioning, and social functioning),
three symptom domains (fatigue, nausea and vomiting,
pain), six further additional cancer associated symptoms
(dyspnea, appetite loss, insomnia, constipation, diarrhea,
financial difficulties) and gives a global value for quality
of life. Thereby as well as in the functioning scales, high
values represent a high quality of life. For symptoms and
symptom scales, high values represent high symptom-
atology. For the current study, only global quality of life,
the functioning scales and the fatigue scale were evalu-
ated (see Table 1).
For interpretation of QLQ C-30 data, reference data
from the German healthy population were used [16].
Additionally, score differences between groups or dif-
ferent time points were analyzed using a classification
of Osoba et al. [17]: From one of their studies it
became apparent that patients experience a difference
in scale values of 5 to 10 points as “a little”, 10 to 20
points as “moderate”, and ≥20 as “very much”. There-
fore, differences of less than 5 points are not clinically
relevant.
Statistical analyses
All questionnaire data were transferred to a Microsoft
Excel table and scored in accordance with the official
EORTC QLQ C-30 manual [15]. With statistical pro-
grams STATISTICA (version 9.1 and 10.0) and the free
programming language R [18] the higher analyses were
carried out. Two independent samples were compared
using the Wilcoxon-Mann-Whitney test, multiple com-
parisons were done with the R package “nparcomp”.
Level of significance was set to α = .05. In this paper,
only those group differences are described which are sta-
tistically and clinically meaningful.
Results
Quality of life in patients and healthy controls
The scale values for global QoL, the six functioning
scales and the symptom scale „fatigue” from the study
sample were compared to a sample from the healthy
German population. These randomly selected 2041
German adults were chosen by using the random-route
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technique (random selection of street, house, flat and
target subject in the household) and provided informa-
tion about their quality of life. According to the authors
the sociodemographic data were representative of the
adult German population [16]. For each scale, a clinically
meaningful difference was found which can be labeled as
“strong” according to Osoba [17]. According to his
research a difference of 5–10 points on a 0–100 point
scale has to be considered as minimally clinically
important. Differences between 10 and 20 points have a
moderate clinical meaning, and >20 points have a strong
clinical meaning. Compared to the healthy population,
global QoL and functioning were remarkably reduced
Table 1 EORTC-QLQ-C30 questionnaire: evaluation of gQoL,

















Fig. 1 Depicts the distribution of T stages (a) and N stages (b) in the study population
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and fatigue was increased in the study population (see
Table 2).
Quality of life in different patient groups
Different socioeconomic parameters were analyzed that
might affect quality of life in cancer patients; these being
Age, Gender, Sex, Tumor Entity, TNM Stage, Previous
Treatment, Time Interval since Diagnosis.
Age:
A comparison of scale values from participants of
different age groups was done. We are only reporting
those results that are statistically and clinically
significant [17]. Participants younger than 39 years had
a slightly higher physical functioning than those older
than 60. Emotional functioning was most impaired in
the 40–59 year olds, while no difference between the
two other groups was found. Social functioning was
most impaired in the youngest group, followed by the
middle and then by the oldest group. Fatigue symptoms
were more pronounced in the middle than in the
youngest group (see Table 3). For each of the age
groups scale values differed significantly from values of
similar age groups in the healthy population. However,
the differences were more pronounced in the youngest
group (≤39) and lowest in the oldest (≥60) for most
scales. These results are shown in Table 4.
Gender:
Between men and women in the study population,
clinically meaningful differences were found for
physical, emotional, cognitive and role functioning as
well as for fatigue. Women reported stronger
impairments than men. All found differences were
classified as minor according to Osoba [17] (see
Table 5).
Diagnosis:
Between patients with different diagnoses, statistically
and clinically meaningful differences concerning
physical, emotional, cognitive, social, and role
functioning as well as fatigue were found. Patients with
prostate carcinoma reported less impairment than
other patient groups in different domains of QoL:
physical and role functioning were moderately
increased compared to patients with breast cancer and
malignancies of the female genital organs; emotional
functioning was much higher than for patients with
malignancies of thyroid and other endocrine glands;
social functioning was moderately increased compared
to patients with malignancies of the female genital
organs; and fatigue symptoms were less distinct than in
patients with breast cancer, malignancies of the female
genital organs, with leukemia/lymphomas, and with
gastrointestinal carcinoma. Patients with malignancies
of thyroid and other endocrine glands reported
decreased emotional functioning compared to patients
with leukemia/lymphomas, with colorectal cancer, and
with gastrointestinal carcinoma. Patients with breast
cancer reported slightly decreased emotional and
cognitive functioning compared to patients with
colorectal carcinoma. Table 6 provides details of these
results.
Previous treatment:
Patients who had undergone radiotherapy and
chemotherapy showed moderately decreased physical
functioning compared to patients with other treatment
methods (radiotherapy only, chemotherapy only, or
other). Other differences were not clinically meaningful
(see Table 7).
Tumor stage and time interval since diagnosis:
Comparing different tumor stages, lymph node
manifestations, and metastatic spread did not show any
significant differences concerning the QoL of patients.
Table 2 Scale mean scores (M) and standard deviations (SD) of
the study population compared to a healthy sample





gQoL 49.2 ± 22.0 70.8 ± 22.1 21.6
PF 66.7 ± 20.9 90.1 ± 16.7 23.4
EF 50.4 ± 28.6 78.7 ± 21.0 28.3
CF 65.5 ± 29.4 91.2 ± 17.0 25.7
RF 51.5 ± 30.9 88.0 ± 22.9 36.6
SF 58.4 ± 32.0 91.0 ± 19.4 32.6
F 56.4 ± 27.6 17.0 ± 22.0 39.4
Abbreviations: gQoL global quality of life, PF physical functioning, EF emotional
functioning, CF cognitive functioning, RF role functioning, SF social
functioning, F fatigue
a Schwarz & Hinz, 2001
Table 3 Contains all clinically meaningful differences in scale
values between participants in different age groups
Score Age a N M± SD p-value Difference
PF ≤39 129 71.7 ± 20.8 .000 7.3
≥60 671 64.5 ± 20.5
EF ≤39 126 54.47 ± 25.7 .007 7.5
40–59 1014 46.9 ± 28.9
40–59 1014 46.9 ± 28.9 .000 8.2
≥60 652 55.0 ± 28.0
SF ≤39 129 52.8 ± 30.1 .001 9.9
≥60 677 62.8 ± 30.8
40–59 1029 56.2 ± 32.8 .000 6.6
≥60 677 62.8 ± 30.8
F ≤39 128 51.1 ± 66.7 .047 6.0
40–59 1039 57.1 ± 77.8
Abbreviations: PF physical functioning, EF emotional functioning, SF social
functioning, F fatigue
a age (years)
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Furthermore, there was no correlation with QoL
regarding the time interval between diagnosis and
rehabilitation.
Improvement of quality of life after rehabilitation
All patients included in this study received a compre-
hensive multi-modal in-patient rehabilitation program
of 3-week duration based on a bio-psychosocial and
positive health concept which was mainly comprised
of psycho-oncological consultations in group and
individual sessions, physical activities like Nordic
Walking, water gymnastics, physiotherapy and (car-
diorespiratory) fitness training as well as vocational
therapy, cognitive treatment and support by a social
worker if needed. Comparing life quality at the begin-
ning and end of our rehabilitation program gQoL and
each functioning scale was significantly improved (p <
00,001). Beside global life quality, emotional function-
ing and role functioning improved the most, i.e.
between 10 and 20 points on the 100 point scale (see
Table 8).
Table 4 Shows mean scale values from the study population compared to the healthy population sample [16] in different age
groups
Score Age a M ± SD study population M healthy population b Difference
gQoL ≤39 53.78 ± 20.34 81.70 27.92
40–59 47.25 ± 22.27 72.85 25.60
≥60 51.33 ± 21.67 63.55 12.22
PF ≤39 71.68 ± 20.80 98.10 26.42
40–59 67.52 ± 21.20 94.30 26.78
≥60 64,50 ± 20,49 82,43 17.93
EF ≤39 54.37 ± 25.71 84.80 30.43
40–59 46.87 ± 28.85 80.15 33.28
≥60 55.02 ± 28.02 81.00 25.98
CF ≤39 68.72 ± 26.98 96.95 28.23
40–59 62.42 ± 30.54 94.30 31.88
≥60 69.72 ± 27.44 86.30 16.58
SF ≤39 52.84 ± 30.13 97.30 44.46
40–59 56.19 ± 32.75 92.85 36.66
≥60 62.75 ± 30.83 86.00 23.25
RF ≤39 54.97 ± 29.83 96.70 41.73
40-59 50.75 ± 31.15 90.80 40.05
≥60 51.88 ± 30.76 81.40 29.52
F ≤39 51.13 ± 27.23 7.60 43.53
40–59 57.12 ± 27.67 12.15 44.97
≥60 56.51 ± 20.34 23.20 33.31
Abbreviations: gQoL global quality of life, PF physical functioning, EF emotional functioning, CF cognitive functioning, SF social functioning, RF role functioning,
F fatigue
a in years
b Schwarz & Hinz, 2001; no SD values given
Table 5 Contains all clinically meaningful score differences for
men and women
Score Sex N M± SD P value Difference
PF Male 533 70.26 ± 21.61 .000 5.01
Female 1299 65.25 ± 20.57
EF Male 528 56.63 ± 28.38 .000 8.88
Female 1264 47.75 ± 28.30
CF Male 534 70.23 ± 27.33 .000 6.60
Female 1307 63.63 ± 29.99
RF Male 524 56.04 ± 31.90 .000 6.52
Female 1289 49.52 ± 30.31
F Male 531 51.04 ± 28.65 .000 7.68
Female 1290 58.72 ± 26.85
Abbreviations: PF physical functioning, EF emotional functioning, CF cognitive
functioning, RF role functioning, F fatigue
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Table 6 Depicts statistically and clinically significant differences in scale values between groups of patients with different
malignancies
Score Diagnosis N M± SD P value Difference
PF Breast cancer 824 66.95 ± 19.58 .035 5.35
Malignancies of female genital organs 174 61.30 ± 20.26
PF Breast cancer 824 66.95 ± 19.58 .033 7.87
Prostate carcinoma 85 74.82 ± 20.12
PF Malignancies of female genital organs 174 61.30 ± 20.26 .000 13.52
Prostate carcinoma 85 74.82 ± 20.12
EF Colorectal carcinoma 211 55.92 ± 28.83 .032 7.09
Breast carcinoma 801 48.28 ± 28.37
EF Colorectal carcinoma 211 55.92 ± 28.83 .002 18.34
Malignancies of thyroid and other endocrine glands 55 37.58 ± 26.88
EF Prostate carcinoma 84 58.73 ± 29.71 .002 21.15
Malignancies of thyroid and other endocrine glands 55 37.58 ± 26.88
EF Hemoblastoses 234 52.03 ± 29.91 .015 14.45
Malignancies of thyroid and other endocrine glands 55 37.58 ± 26.88
EF gastrointestinal carcinoma 93 54.39 ± 29.09 .019 16.81
Malignancies of thyroid and other endocrine glands 55 37.58 ± 26.88
CF Colorectal carcinoma 216 71.45 ± 27.28 .006 8.96
Breast cancer 826 62.49 ± 30.19
SF Malignancies of female genital organs 170 51.57 ± 33.00 .039 14.14
Prostate carcinoma 87 65.71 ± 29.24
RF Breast cancer 820 51.10 ± 29.56 .044 11.35
Prostate carcinoma 87 62.45 ± 31.15
RF Malignancies of female genital organs 168 48.12 ± 31.61 .025 14.33
Prostate carcinoma 87 62.45 ± 31.15
F Breast cancer 822 57.88 ± 26.77 .005 13.31
Prostate carcinoma 87 44.57 ± 28.73
F Malignancies of female genital organs 169 59.17 ± 25.96 .007 14.60
Prostate carcinoma 87 44.57 ± 28.73
F Prostate carcinoma 87 44.57 ± 28.73 .008 14.19
Hämoblastosen 239 58.76 ± 27.83
F Prostate carcinoma 239 44.57 ± 28.73 .017 15.50
gastrointestinal carcinoma 91 60.07 ± 27.67
Abbreviations: PF physical functioning, EF emotional functioning, CF cognitive functioning, SF social functioning, RF role functioning, F fatigue
Table 7 Shows the difference in physical functioning between patients with radio- and chemotherapy compared to patients with
other treatments
Score Chemo- and radiotherapy a N M± SD Median Q25 Q75 p- value Difference
PF no 1263 67.75 ± 20.90 66.67 53.33 86.67 .001 19.36
yes 563 48.39 ± 21.08 66.67 46.67 80.00
Abbreviation:PF physical functioning
a yes = combination of chemotherapy and radiotherapy, no = any other treatment
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Discussion
Having a look at our study population, it becomes clear
that the distribution of neither tumor sites nor sex is
representative for cancer in general. This is due to a
specialization for breast cancer in the study center.
Nevertheless, we believe that the registered data are suf-
ficient to deduce some general knowledge about
HRQOL in oncological patients.
Patients in the current study scored significantly lower
in all domains of HRQOL than the healthy German
population. Certainly, the overrepresentation of women
in the study group has put a possible bias on the results,
because it has often been shown that women regularly
report lower quality of life than men on average [16].
This has been confirmed in this study. So perhaps the
discrepancy of values between our study group and the
healthy population has been slightly overestimated.
Nevertheless, the results show a distinct impairment of
different areas of life following cancer and treatment.
Some patient characteristics can be identified which hint
to a particularly high impairment and need of support.
At first sight, regarding the age groups of our study
participants, it is difficult to identify a certain trend of
age related changes in HRQOL, as there are only minor
advantages for different groups in different domains.
However, a trend becomes apparent when one compares
the age related changes in the study group with those of
the healthy population. While in all age groups the study
group differs significantly from the healthy population,
this difference is by far more pronounced in younger
than in older age groups for most of the scales. These
results go in line with those of Curt et al. [7] who report
that younger tumor patients more often complain about
depression, hopelessness and suicidal tendencies than
older patients and they feel more limited in social activ-
ities. Even the difference in physical functioning dimin-
ishes with increasing age although more severe side
effects (e.g. heart failure, polyneuropathy) can be ex-
pected for chemo- and radiotherapy in older age patients
[19, 20]. As differences between the age groups of cancer
patients are not very distinct, but a distinct change in
the difference between patients and healthy population
exists, it has to be assumed that this is due to age-
related changes of HRQOL in the healthy population
[21]. Maybe in the oldest age group the reference group
should not be referred to as “healthy population” as the
prevalence of chronic diseases and additional handicaps
generally increase in older people, which may then lead
to overall decreasing HRQOL. Hence in this group it is
not even sure how much HRQOL is specifically im-
paired by the cancer disease considering the eventuality
of other handicaps. On the contrary, members of the
youngest and middle age group are compared with
people of a life stage that is normally characterized by
maximum independency and strength [22]. Here, the
discrepancy between the “image of being young, healthy
and beautiful” and the actual situation of a cancer pa-
tient suffering, for example, from pronounced fatigue
after intense treatment, is very obvious. Treatment in
younger patients is often intensive, multimodal and
lengthy. The diagnosis of cancer affects young patients
in a vulnerable phase of their life when their normal pri-
vate (e.g. partnership) and professional development is
interrupted. Thus, healthcare providers should be aware
of the symptom burden in this special patient group and
regularly monitor HRQOL in young patients to direct
attention to psychosocial and vocational problems and
ascertain holistic care in this special population.
Table 8 Depicts mean quality if life scores before (pre) and after (post) rehabilitation
Rehabillitation N M± SD Median Q25 Q75 P- value Δ
pre gQoL
post gQoL
1850 49,22 ± 22,05 50,00 33,33 66,67 0000 11,84
1578 61,06 ± 20,16 66,67 50,00 75,00
pre PF
post PF
1832 66,71 ± 20,99 66,67 53,33 80,00 0000 6,70
1561 73,41 ± 18,97 73,33 60,00 86,67
prae EF
post EF
1792 50,37 ± 28,61 50,00 25,00 75,00 0000 16,29
1531 66,66 ± 26,70 66,67 50,00 91,67
prae SF
post SF
1835 58,37 ± 32,05 66,67 33,33 83,33 0000 9,07
1559 67,44 ± 29,54 66,67 50,00 100,00
prae KF
post KF
1841 65,54 ± 29,39 66,67 50,00 83,33 0000 5,35
1573 70,89 ± 27,66 83,33 50,00 100,00
prae RF
post RF
1813 51,46 ± 30,93 50,00 33,33 66,67 0000 13,69
1535 65,15 ± 28,59 66,67 50,00 100,00
prae F
post F
1821 56,47 ± 27,61 55,56 33,33 77,78 0,000 8,68
1553 65,15 ± 26,51 33,33 22,22 66,67
Abbreviations: gQoL global quality of life, PF physical functioning, EF emotional functioning, CF cognitive functioning, RF role functioning, F fatigue
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Concerning tumor site, a trend for patients with pros-
tate carcinoma reporting less impairment in the different
domains of HRQOL than patients with other diagnoses
becomes apparent. This goes in line with findings of
other studies [23]. Why would that be? The general
prognosis of prostate carcinoma is comparably positi-
ve—but nevertheless, it does not differ much from that
of breast cancer [24, 25]. In addition, many men suffer
from potency problems after having their prostate car-
cinoma treated which may correspond to the loss of fe-
male identity in women after breast surgery. There may
be other reasons why these patients still score higher on
the different domains of HRQOL. First, the prognosis of
prostate carcinoma is more positive compared to some
of the other diagnoses. Second, this specific group of pa-
tients consists of men only whereas all other groups
contain at least some women. As we already mentioned,
women tend to report lower HRQOL than men in gen-
eral. Third, chemotherapy which (in combination with
radiotherapy) causes some of the most severe sequelae
in treatment of cancer is rarely applied in prostate
carcinoma.
Concerning treatment methods, we found that the
combination of chemotherapy and radiotherapy has a re-
markably diminishing effect on physical functioning
compared to all other treatments while radiotherapy and
chemotherapy alone do not. Furthermore, Cancer-
related fatigue (CRF) seems to be more pronounced in
this treatment regime. It is known that CRF predicts
lower physical functioning [26, 27] and that after chemo-
therapy and radiotherapy 80 % and 90 % suffer from
CRF, respectively [5, 8, 28, 29]. Hence, the combination
of chemo- and radiotherapy may aggravate CRF and
therefore aggravate impairment of physical functioning.
Surprisingly, although one could have expected a
lower HRQOL in patients with a more advanced tumor,
nodes and metastases stages, these factors did not seem
to influence the domains of HRQOL. In some way this
corresponds to our clinical perception, which we often
experience that patients with early stage cancer and best
prognoses are as frightened of progression and tumor
recurrence and afraid of death as patients at a later
stage. This probably goes back to the previously de-
scribed fact that cancer is by far the most feared disease
in Germany and is mostly thought of as lethal whereas
information about developing treatment methods and
improving prognoses are not that far spread. Further-
more, the composition of the study group may play a
role in this result because most of the participants had
low tumor stages (1–2), few affected lymph nodes (stage
0–1) and no metastases at all; so the weight of extremely
affected participants in the statistical analyses is very
low. Another theory which becomes more and more im-
portant in the field of HRQOL and which can be taken
for a possible explanation is that of response shift.
During the period of (chronic) illness patients gradually
change their expectancies and values which can lead to a
different concept of HRQOL [30]. Therefore they can
still reach similar scores in different HRQOL domains as
before but with a different meaning.
From our point of view, perhaps the most important
result is that HRQOL does not seem to improve spon-
taneously over at least the first 16 months on average
after diagnosis of cancer. Although most patients in our
study have been treated curatively, so that most of them
will probably survive their cancer, their life quality
remained strongly impaired for many months after diag-
nosis. This finding is in agreement with other studies
[31, 32] and highlights the importance of HRQOL
screening and HRQOL specific intervention for onco-
logical patients. Even long-term cancer survivors might
profit from rehabilitative intervention. However 46 % of
German cancer survivors feel inadequately informed
about support offers with their lack of knowledge being
mostly associated with older age and lower education
[31]. This is particularly important because patients may
benefit with regard to their HRQOL from a short in-
tense intervention like a 3 week rehabilitation program
as could be shown in our study. Coping and empower-
ment are key factors within rehabilitation. Substantial
components of the rehabilitation are also aerobic phys-
ical activities like Nordic Walking, water gymnastics,
(cardiorespiratory) fitness training as well as muscle
strength training. A positive influence of physical activity
on CRF, physical distress, physical functioning and
HRQOL has been shown repeatedly [33–35]. Additionally,
there are several components which could be classified as
belonging to so-called integrative (complementary) medi-
cine: where in regular psycho-oncological sessions and, if
needed, individual care can be given. Furthermore,
patients can benefit from traditional Chinese medicine
(acupuncture), dance therapy or art therapy which can
also positively influence HRQOL by helping the patient
finding some deeper meaning of his or her illness. The
meaning building process is actually discussed as one
main factor for successful coping. All those intervention
components are not necessarily bound to inpatient
rehabilitation but can also be integrated in ambulant care.
In addition, screening for psychological and physical im-
pairments will allow tailoring rehabilitative procedures for
individual needs.
While oncological treatment methods will develop fur-
ther to a so called “individualized therapy”, integrative
treatment modalities are still somehow neglected. Today,
the term “individualized or personalized therapy” stands
for therapy based on individual biomarkers. The idea or
concept of “individualized therapy” is however broader,
reflecting a therapy of individual patient’s needs. The
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development to a broader understanding of this term
and to an anchorage of integrative holistic medicine in
oncological care routine has to take place to be able to
not only support patients on the somatic but also on the
psychosocial level. Monitoring HRQOL can help cancer
patients to communicate concerns and symptoms to
health care providers that might not be otherwise dis-
cussed. Screening for impairments in HRQOL might be
a valuable simple tool for detecting those in need of spe-
cial medical attention and complex rehabilitation inter-
ventions. Young female patients having been treated
with chemo- and radiotherapy can probably benefit the
most regardless of the objective severity of their cancer
disease as also has been discussed by Silver et al. [36].
There are some limitations to this study. First, we ana-
lyzed patient characteristics separately and not in some
kind of multiple regression analysis. Thus, we can only re-
port separate findings although it is likely and in some
cases even certain that patient characteristics are interre-
lated (e.g. diagnosis and sex). Future studies should
broaden their approach in this regard. Second, the study is
based on a selective subpopulation of patients who under-
went inpatient rehabilitation. In Germany, the percentage
of oncological patients undergoing inpatient rehabilitation
has declined to only 1/3 in the last few years [31]. It is not
yet known which factors influence utilization of rehabilita-
tion, but one might speculate that these patients actively
seek help from their doctors and are therefore psycho-
logically more strained and/or better informed about re-
habilitation programs than others. Thus, generalization of
our study results has to be done with caution.
Conclusion
Persistent and comprehensive impairment of HRQOL in
cancer patients on the one hand and the various inter-
vention possibilities on the other hand underline the im-
portance and practicability of a broader consideration of
HRQOL as patient reported outcome parameter during
and after cancer treatment. Standardized screening in-
struments like the EORTC QLQ C-30 represent a simple
and economic way of screening for physical and psycho-
logical impairments and offering appropriate (tailored)
intervention programs if needed. The implementation of
efficient networks of (ambulant) health-care providers
(primary care physicians, clinical oncologists, nurse
practitioners, mental health professionals) is urgently
needed, in particular since the number of cancer survi-
vors is steadily increasing and many of them have or will
have multiple impairments.
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